Disc Medicine Appoints Biopharma Veteran Nadim Ahmed To Board Of Directors

Disc Medicine, Inc., a clinical-stage biopharmaceutical company specializing in treatments for serious hematologic disorders, has appointed Nadim Ahmed to its Board of Directors. Mr. Ahmed currently serves as President and CEO of Cullinan Therapeutics, which is advancing a pipeline of oncology and autoimmune programs. His appointment brings additional strategic and operational expertise to Disc Medicine’s leadership team.

“With multiple meaningful catalysts expected in the coming months, including a potential NDA filing and launch for bitopertin in EPP, I am thrilled to be joining the Board of Disc at this exciting time. I look forward to partnering with the team as they work to transition Disc to a commercial-stage company and deliver on the full potential of its rich development pipeline,” said  Mr. Ahmed.

Mr. Ahmed brings over 25 years of experience in the pharmaceutical and biotech industries, with a focus on drug development and commercialization. Before joining Cullinan, he held leadership roles at major companies including Bristol Myers Squibb and Celgene Corporation, where he led hematology and oncology business units. At these organizations, he played a key role in multiple successful product launches and was part of their executive leadership teams.

“I am excited to welcome Nadim to Disc’s Board of Directors at such a pivotal moment for the company. His track record of successful drug launches and deep expertise in hematological diseases will be invaluable as we advance bitopertin towards commercialization in EPP and continue development of the rest of our hematology pipeline,” said John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc. 

Mr. Ahmed holds advanced degrees in science from institutions in the United Kingdom, including an MSc from Loughborough University and a BSc from University College London. His addition to Disc Medicine’s board is expected to support the company's continued progress as it advances its pipeline toward commercialization in hematology.